5-[N-(n-Propyl)-2-oxo-3-pyrrolin-4-yl]amino-1-(n-pentyl)-4-cyanopyrazole | 89159-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[N-(n-Propyl)-2-oxo-3-pyrrolin-4-yl]amino-1-(n-pentyl)-4-cyanopyrazole
• 英文别名: 5-[(5-oxo-1-propyl-2H-pyrrol-3-yl)amino]-1-pentylpyrazole-4-carbonitrile
• CAS: 89159-04-6
• 化学式: C₁₆H₂₃N₅O
• 分子量: 301.392
• InChiKey: JGEGFRHDQVVYDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-[N-(n-Propyl)-2-oxo-3-pyrrolin-4-yl]amino-1-(n-pentyl)-4-cyanopyrazole 在 cadmium(II) chloride 作用下， 以 四氢呋喃 为溶剂， 生成 4-Amino-6,7-dihydro-1-pentyl-6-propylpyrazolo<3,4-b>pyrrolo<3,4-e>pyridin-5(1H)-one
  参考文献：
  名称：

  Synthesis of Tricyclic Aminopyridines by a Cadmium Promoted Cyclization

  摘要：

  A novel cyclocondensation of o-amino nitriles with cyclic 1,3-diones has been developed as a synthetic route to assemble fused tricyclic aminopyridine derivatives. The reaction sequence involves the initial formation of an enaminone. The enaminone is then cyclized at 120 degrees C to 190 degrees C in the presence of Lewis acids which include zinc, cadmium and copper(I) salts. The cyclization may be promoted under more mild conditions by first deprotonating the enaminone to form the anion followed by exposure to cadmium(II) salts at 60 degrees C to 90 degrees C. Alternatively the enaminones may be reacted with organocadmium reagents such as dibutylcadmium to effect the deprotonation and cyclization directly at room temperature. Synthetic applications of these novel cadmium-mediated cyclizations are presented and mechanistic considerations discussed.

  DOI：

  10.1021/jo00121a048
• 作为产物：
  描述：

  5-Amino-4-cyano-1-(n-pentyl)pyrazole 、 1-丙基吡咯烷-2,4-二酮 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 5-[N-(n-Propyl)-2-oxo-3-pyrrolin-4-yl]amino-1-(n-pentyl)-4-cyanopyrazole
  参考文献：
  名称：

  Synthesis of Tricyclic Aminopyridines by a Cadmium Promoted Cyclization

  摘要：

  A novel cyclocondensation of o-amino nitriles with cyclic 1,3-diones has been developed as a synthetic route to assemble fused tricyclic aminopyridine derivatives. The reaction sequence involves the initial formation of an enaminone. The enaminone is then cyclized at 120 degrees C to 190 degrees C in the presence of Lewis acids which include zinc, cadmium and copper(I) salts. The cyclization may be promoted under more mild conditions by first deprotonating the enaminone to form the anion followed by exposure to cadmium(II) salts at 60 degrees C to 90 degrees C. Alternatively the enaminones may be reacted with organocadmium reagents such as dibutylcadmium to effect the deprotonation and cyclization directly at room temperature. Synthetic applications of these novel cadmium-mediated cyclizations are presented and mechanistic considerations discussed.

  DOI：

  10.1021/jo00121a048

文献信息

• Process for preparing pyrazolopyridine compounds
  申请人：ICI Americas Inc.

  公开号：US04563525A1

  公开（公告）日：1986-01-07

  Compounds of the formula (I): ##STR1## wherein R.sup.4 is hydrogen, D is oxygen or NR.sup.6, R.sup.1, R.sup.3, R.sup.6, R.sup.7 and R.sup.8 have defined values, and n is 1 or 2 are produced by internally cyclizing a compound of the formula (XV): ##STR2## wherein R.sup.19 is a value of R.sup.1 or hydrogen and, if R.sup.19 is hydrogen, reacting the cyclization product with R.sup.1 --Br and a weak base such as potassium carbonate.

  公式（I）的化合物：##STR1## 其中R.sup.4是氢，D是氧或NR.sup.6，R.sup.1，R.sup.3，R.sup.6，R.sup.7和R.sup.8具有定义的值，n为1或2，通过内部环化化合物的方法制备（XV）的化合物：##STR2## 其中R.sup.19是R.sup.1或氢的值，如果R.sup.19是氢，则将环化产物与R.sup.1-Br和弱碱（如碳酸钾）反应。
• CNS-Depressant pyrazolopyridines
  申请人：ICI Americas Inc.

  公开号：US04511568A1

  公开（公告）日：1985-04-16

  Compounds of the formula (I): ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.7 and R.sup.8 are as described herein, D is oxygen or NR.sup.6, n is 1 or 2 and the physiologically acceptable salts thereof useful in reducing anxiety in an animal such as man. The compounds are potent anxiolytics having reduced side effects compared to known anxiolytics. Also pharmaceutical compositions, intermediates and methods of treatment and synthesis are described.

  公式(I)的化合物：##STR1##其中R.sup.1、R.sup.3、R.sup.4、R.sup.7和R.sup.8如本文所述，D是氧或NR.sup.6，n为1或2，以及其生理上可接受的盐，有助于减少动物（如人类）的焦虑。这些化合物是具有减少副作用的强效抗焦虑剂，与已知的抗焦虑剂相比。还描述了药物组合物、中间体和治疗和合成方法。
• Pyrazolopyridine compounds
  申请人：ICI AMERICAS INC.

  公开号：EP0094175A1

  公开（公告）日：1983-11-16

  Compounds of the formula (I): wherein D is oxygen or NR6, R1, R3, R4, R6, R7 and R8 have defined values, and n is 1 or 2, and pharmaceutically-acceptable acid-addition salts thereof, processes for their preparation, pharmaceutical compositions, and intermediates for preparing said compounds of the formula (I). The compounds of the formula (I) are central nervous system depressants, for example, anxiolytic agents.

  式(I)化合物： 其中 D 是氧或 NR6，R1、R3、R4、R6、R7 和 R8 具有定义值，n 是 1 或 2，以及其药学上可接受的酸加成盐、其制备工艺、药物组合物和制备所述式 (I) 化合物的中间体。式（I）化合物是中枢神经系统抑制剂，例如抗焦虑剂。
• ——
  作者：

  DOI：——

  日期：——
• CAMPBELL, J. B. ,, JR.
  作者：CAMPBELL, J. B. ,, JR.

  DOI：——

  日期：——